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Acronyms: ALS=amyotrophic lateral sclerosis; FALS=familial ALS; FTD=frontotemporal 
dementia; FTLD=frontotemporal lobar dementia; LMN=lower motor neuron; PLS=primary lateral 
sclerosis; PMA=progressive muscular atrophy; SALS=sporadic ALS; UMN =upper motor neuron 3	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ABSTRACT 
Amyotrophic lateral sclerosis (ALS) is characterized phenotypically by progressive weakness 
and neuropathologically by loss of motor neurons. Phenotypically, there is marked 
heterogeneity. Typical ALS has mixed upper motor neuron (UMN) and lower motor neuron 
(LMN) involvement. Primary lateral sclerosis has predominant UMN involvement. Progressive 
muscular atrophy has predominant LMN involvement. Bulbar and limb ALS have predominant 
regional involvement. Frontotemporal dementia has significant cognitive and behavioral 
involvement. These phenotypes can be so distinctive that they would seem to have differing 
biology. But they cannot be distinguished, at least neuropathologically or genetically. In sporadic 
ALS (SALS), they all are characterized by ubiquitinated cytoplasmic inclusions of TDP-43. In 
familial ALS (FALS), where phenotypes are indistinguishable from SALS and similarly 
heterogeneous, each mutated gene has its own genetic and molecular signature. Putting this 
together, since the same phenotypes can have multiple causes including different gene 
mutations, there must be multiple molecular mechanisms causing ALS and ALS is a syndrome. 
But since multiple phenotypes can be caused by one single gene mutation, a single molecular 
mechanism can cause heterogeneity. What the mechanisms are remain unknown, but active 
propagation of the pathology neuroanatomically seems to be a principle component. Leading 
candidate mechanisms include RNA processing, cell-cell interactions between neurons and 
non-neuronal neighbors, focal seeding from a misfolded protein that has prion-like propagation, 
and fatal errors introduced during neurodevelopment of the motor system. If fundamental 
mechanisms can be identified and understood, ALS therapy could rationally target progression 
and stop disease—a goal that seems increasingly achievable. 
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INTRODUCTION 
	 ﾠ
The chief characteristic that defines amyotrophic lateral sclerosis (ALS) is progressive 
weakness from neurodegeneration of the upper motor neuron (UMN) and lower motor neuron 
(LMN). Clinically, this is defined by a history establishing weakness over time and space, and by 
an examination showing signs of both UMN and LMN dysfunction in one or more body regions. 
Neuropathologically, ALS is defined by loss of motor neurons in brain, brainstem, and spinal 
cord and now increasingly by a sophisticated repertoire of neuropathological markers. Clinical 
phenotypes are determined by the anatomic location of neuropathology and during life, this 
anatomic pathology can be imputed clinically.  
 
Heterogeneity of clinical phenotypes is characteristic—there are vastly different degrees of 
involvement of UMN and LMN, body regions that are affected, degrees of involvement of other 
systems especially cognition and behavior, and progression rates. While there are highly 
distinctive molecular neuropathological subtypes of ALS, in fact most of the known 
neuropathology seems more homogeneous than heterogeneous and does not clearly correlate 
with the various clinical phenotypes. This is the main mystery: is it one disease with shared 
fundamental biologic mechanisms or is it many diseases with different fundamental 
mechanisms and if so, how do they relate?  
 
Genetics is giving us clues—clinical phenotype both masks and unmasks essential elements 
and there must be both single mechanisms and multiple mechanisms! Sporadic ALS (SALS), 
which is 90% of cases, and familial ALS (FALS), which is 10%, are indistinguishable from each 
other by phenotype. The fact that many different gene mutations have identical or at least highly 
similar clinical phenotypes tells us there must be multiple mechanisms that cause ALS and ALS 
is a syndrome. But the fact that one single genotype causes many different phenotypes tells us 5	 ﾠ
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that single mechanisms can lead to multiple phenotypes. Mechanisms both converge and 
diverge 
 
CLINICAL PHENTOYPES 
Clinical Phenotypes Based on Level of Involvement 
 
“Typical” ALS (Tables 1 and 2): Weakness in classical ALS has simultaneous UMN and LMN 
characteristics. The weakness typically begins insidiously in discrete body regions and 
advances steadily over time and space. It begins in any of the three main body regions (face, 
arm and leg) although occasionally begins in the muscles affecting the trunk and/or respiration. 
This has been codified into the El Escorial criteria, which underscores that defining ALS 
syndromes is largely clinical and that the physical examination signs are critically important. The 
co-mixture of UMN and LMN clinical signs, indicating the degree to which the pathological 
burden is distributed between one level and the other, is normally distributed, with a possible 
skew to LMN predominance (1). At the extremes, when disease is predominantly UMN or 
predominantly LMN, there are special designations, highlighting the uniqueness and raising the 
question of whether or not these are fundamentally different biologically or the extremes of one 
continuum.  
 
Primary lateral sclerosis (PLS) (Tables 1 and 2): PLS is the designation for a syndrome with 
solely UMN level phenotype and it remains unknown whether it is a discrete syndrome or a 
variant of ALS (2-7). In over half of PLS patients, symptoms begin insidiously in the legs and 
ascend smoothly and relatively symmetrically to arms and bulbar muscles. Others have a 
patchy progression, often with prominent bulbar symptoms. There is disagreement as the 
degree of LMN involvement especially as identified by EMG findings (8, 9). Patients with 
clinically pure PLS and no EMG changes four years after symptom onset have decades-long 6	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survival (8, 10), whereas minor EMG or LMN findings predicted a poorer prognosis, consistent 
with typical ALS patients presenting with predominant UMN signs (11). Thus, the diagnosis of 
PLS should be made only after four years of disease duration (8). PLS may stabilize after a few 
years of progression (12), although similar stabilization may occur in UMN-dominant ALS (UMN-
D ALS) (11, 13). Frontotemporal dementia (FTD), cognitive impairment and altered behavior 
occur in PLS comparable to ALS (14). Ultimately, PLS is a clinical diagnosis that relies upon 
exclusion of other known causes of progressive spasticity, such as sporadic presentations of 
hereditary spastic paraparesis (15).  
 
Progressive muscular atrophy (PMA) (Tables 1 and 2): PMA is the designation for syndromes 
with predominantly LMN phenotype. Onset can be in any body region and compared to ALS, 
PMA patients are more likely to be men and have a higher age of onset. Approximately 30% of 
PMA patients develop UMN signs within 18 months (16, 17).
 A subset of patients that is 
characterized by segmental involvement for more than 4 years duration have slow progression 
and prolonged survival, though transition to ALS can occur even in this group (18, 19). Patients 
with PMA demonstrate the same frontotemporal pattern of cognitive involvement as is seen in 
typical ALS and thus the degree of UMN involvement does not correlate with cognitive 
involvement (20). The UMN imaging data is not straightforward. Depending on technique, 
changes may not be seen (21), may predate clinical changes (22), or may show extra-motor 
white matter involvement (23). By MR spectroscopy, one study showed changes in 63% of PMA 
patients (24) and another study showed only modest, nonsignificant changes (25). 
Neurophysiological studies of central motor conduction using transcranial magnetic stimulation 
show abnormalities in 50 - 63% of patients with clinical PMA (24, 26).  
 
Clinical Phenotypes Based on Body Region of Involvement 
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Bulbar and pseudobulbar palsy (Tables 1 and 2): While the designations PLS and PMA are 
based on the level of the underlying pathology, another set of designations is based on the body 
region first affected at the outbreak of disease. When ALS begins by affecting the muscles of 
speech, mastication and swallowing, it is designated bulbar-onset ALS. The designation bulbar 
has traditionally signified predominantly LMN involvement and the designation pseudobulbar 
has traditionally signified predominantly UMN involvement, but often bulbar is used as parlance 
for both. EMG positive (meaning LMN is involved) and EMG negative (meaning only UMN 
involvement) have similar progression. Interestingly, there is a female predominance in bulbar 
palsy, compared with other limb regional forms where there is male predominance. The bulbar 
system is more complicated than the arms and legs and thus is more than just a fifth limb. 
Bulbar onset is more highly associated with affect and cognition and often has the added 
feature of altered and exaggerated emotional expression that is called emotional incontinence 
and delineation has permitted a clearer understanding of the natural history (27). Bulbar 
symptoms are often directly correlated with depression. Neurophysiological studies have 
identified neural networks underlying corticobulbar control of swallowing that are especially 
affected during repetitive movements (28). Functional MRI studies of the course of bulbar and 
limb- onset ALS are providing insights into the interrelationship between brainstem derived and 
spinal cord derived neural networks (29). A treatment based on dextromethorphan has an 
attenuating effect on pseudobulbar affect.  
 
Limb regional variants including flail leg, flail arm, polyneuritic pattern, and hemiplegia (Mills’s 
variant) (Tables 1 and 2): When ALS begins by affecting muscles of the limbs, as it does two 
thirds of the time, it is referred to as limb-onset, or typical, ALS as discussed above. But within 
this group, a few variant phenotypes have stood out and been given special designations, with a 
view that these variants may have variant biology. Typically these variants are predominantly 
LMN syndromes and tend to be very slowly progressive.  8	 ﾠ
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Upper Extremity Regional Variant: This is a regional variant consisting of weakness exclusively 
confined initially to the upper extremities and cases have also been described under the names 
of “hanging arm syndrome”, “neurogenic man-in-the-barrel”, “flail arm syndrome”, “brachial 
amyotrophic diplegia”, and the “Vulpian-Bernhart syndrome”. These patients have bilateral 
upper extremity weakness and atrophy that affects predominantly the proximal arms and 
shoulder girdle (19, 30). The average age of onset does not differ from that of ALS, but 
compared with ALS, this syndrome is significantly more common in men. Average survival is 
approximately 5 years, however, the definitions used for these patients has been slightly 
different. Some patients presenting with this phenotype can go on to develop a typical ALS 
course. Katz et al used an 18-month time of weakness confined to the arms, and no UMN signs; 
Wijeskera used 12 months and patients could have UMN signs. In the original series of Katz, 
after a mean follow-up of 5.5 years, weakness remained restricted to the upper extremities in 7 
out of 19 patients. 
Lower Extremity Regional Variant: This LMN variant confined to the legs is known as the 
pseudopolyneuritic variant of ALS, the Marie-Patrikios form, flail leg syndrome, the peroneal 
form of ALS, and leg amyotrophic diplegia (19, 31, 32). It is rare (about 3-3.5% of all motor 
neuron disease cases), predominantly male, predominantly LMN, and relatively slowly 
progressive with mean survival ranging from 76 to 96 months. 
Mill’s Variant (Hemiplegic ALS): This is a disputed rare variant phenotype characterized by a 
progressive hemiplegic pattern of motor deficit that ascends from the leg or descends from the 
arm. This could represent a variant of PLS. The scarce literature that exists suggests that it is 
simply a descriptive clinical term. A PET study in one such patient demonstrated a striking 
lateralization of microglial activation in the hemisphere contralateral to the hemiplegia (33). 
 
Clinical Phenotypes with Involvement of Non-Motor Regions 9	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Frontotemporal dementia (Tables 1 and 2): The overlap of FTD and ALS has been well 
documented in FTD patients with co-morbid motor neuron degeneration and in ALS patients 
with frontotemporal dysfunction (34-37). Up to 15% of FTD patients and 30% of ALS patients 
experience the overlap syndrome. The syndrome may be difficult to identify since ALS patients’ 
behavioral or cognitive abnormalities may be subtle and since patients often present either to a 
neuromuscular clinic or a memory disorders center. New designations called behaviorally 
impaired and cognitively impaired ALS were created to reflect uncertainty as to whether or not 
they may have different underlying biologies (38). Key tests that are useful looking for cognitive 
behavioral impairment and excluding depression are beginning to emerge (39). Survival is 
impacted for both disorders in the co-morbid condition, making identification of this syndrome 
critical. There is a survival difference of more than a year between patients with comorbid 
disease versus ALS alone (40).  
 
  Other system involvement: In addition to dementia, other systems can be involved in what 
otherwise seems to be typical ALS. These include the extrapyramidal motor systems (41-47), 
supranuclear gaze systems (48-51) and the autonomic nervous system (52, 53). Increasingly, 
defects in energy metabolism including weight loss, hypermetabolism and hyperlipidemia have 
been identified and implicate either that other CNS regions such as hypothalamus are involved 
or that ALS is part of a systemic disease or both (reviewed in (54)). Such “atypical” involvement 
is sometimes referred to as “ALS-plus syndromes” but there is ample clinical, neuropathologic 
and neuroimaging evidence to suggest that these should be considered to be part of the 
neuropathologic spectrum of ALS/MND (55).  
 
MOLECULAR NEUROPATHOLOGY 
 
Overview neuropathological heterogeneity  10	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Clinical phenotypes are based on the anatomy of the neuropathology imputed by clinical 
localization early in the disease course as summarized in Table 2—actual neuropathology is 
studied after changes have summated over time through the course of the disease. Surprisingly 
little data is available on their correlations. Neuropathologically, ALS is defined as the loss of 
UMNs (commonly thought of as Betz cells in layer V of area 4 of Brodmann) and LMNs 
(commonly thought of as alpha motor neurons in the motor nuclei of the brainstem and Rexed 
Lamina IX of the anterior horns in the spinal columns). Wallerian/axonal degeneration in the 
projecting pathways from the UMN is seen in the corpus collosum, centrum semiovale, internal 
capsule, cerebral peduncle, basis pontis, medullary pyramids and lateral columns (“lateral 
sclerosis”) and similarly degeneration in the projections from the LMN is seen in the anterior 
roots and peripheral nerve, leading to muscle denervation (“amyotrophy”). In addition, there is 
astrogliosis, spongiosis, and microglial activation, which are thought to represent mainly 
secondary reactive changes, at least neuropathologically, although basic research is supporting 
a more primary role for non-neuronal cells. The neuropathology that is reported on PMA and 
PLS suggests these ALS clinical phenotypes share a similar neuropathology and their 
differences are more likely based on the anatomical distribution of the pathological burden than 
on biological differences selecting one level or region over another or on the molecular 
characteristics. PMA neuropathology may show abnormalities of the UMN by way of CD68 
staining of the descending corticospinal tract, abnormalities identified in 50% of patients with 
clinically isolated LMN disease (56). Distinct pathological change is identified in the motor and 
extra-motor areas of the brains as well as the spinal cords of patients whose disease was 
clinically limited to the LMN and these changes seem independent of progression rate (57). PLS 
neuropathology shows changes in the LMN and these changes are of the same molecular 
pattern as is seen in typical disease (58, 59).  
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Distinctive molecular neuropathological types (Table 3) 
 
In 1988, Leigh et al and Lowe et al, independently identified depositions of ubiquitin in the 
cytoplasm of ALS motor neurons using immunohistochemistry (60, 61). The morphologies of the 
deposits were either skein-like or dense and round. Ubiquitin is a housekeeping protein involved 
in protein homeostasis and the finding suggested an unknown pathological protein was being 
tagged for removal by the cell. Similar changes of ubiquitinated aggregates were soon identified 
in about 50% of brains from FTD patients (discussed below). In 2006, the identity of the 
ubiquitinated protein in both diseases was found to be TDP-43, a nuclear protein involved in 
DNA and RNA processing and that in these diseases translocated to the cytoplasm, became 
cleaved, hyperphosphorylated and insoluble (62, 63). Our current molecular neuropathological 
classification is likely to be continually modified: it now appears that the other proteins beside 
TDP-43 may be ubiquitinated; newer markers are being identified; and abnormal TDP-43 may 
be seen in other neurodegenerations. But for now, overall, essentially all sporadic ALS and 
nearly all familial ALS except SOD1- and FUS- associated ALS, regardless of clinical phenotype 
including PLS and PMA, seems to have as its hallmark neuropathological pattern deposition of 
ubiquitinated TDP-43 in the cytoplasm of CNS cells, leading to a belief that ALS is a TDP-43 
proteinopathy. Heat maps of the distribution of TDP-43 pathology show that abnormalities are 
widely present in the brain, not just in motor regions (64).  
 
GENETICS  
 
Clinical Phenotypes Based on Genetics 
 
Five to 10% of ALS is genetically transmitted mainly by way of dominant gene mutations and 
these numbers increase to as high as 15-20% when known genes are tested in patients who were 12	 ﾠ
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thought to have sporadic disease. Approximately 60-70% of the genes have now been identified, 
the main ones being SOD1, TARDBP, FUS and C9ORF72 (reviewed in (65)). Clinical phenotype 
heterogeneity of FALS is as characteristic and vast as SALS, and no clinical features easily 
distinguish one from another. Remarkably, this clinical phenotype heterogeneity is even seen in 
the same mutation in the same gene in the same kinship, implying phenotype is likely determined 
by factors other than the molecular cascade it triggers. But some trends exist. Mutations in SOD1 
and FUS tend to cause predominantly LMN syndromes. Mutations in TARDBP tend to begin in 
the upper extremity and to progress slower than average (66). Mutations in SOD1, TARDBP and 
FUS cause mostly motor syndromes and are only rarely associated FTD. Mutations in FUS cause 
a juvenile as well as adult motor neuron disease syndrome. Mutations in C9ORF72 are as likely to 
cause FTD as ALS, often with psychosis. The ‘A4V’ mutation in SOD1 ALS is rapid while the 
‘D90A’ mutation, unusual in that it is recessive, is slow and indolent.  
 
Genetically defined ALS neuropathology (Table 3) 
 
Whereas gene mutations do not directly correlate with clinical phenotype, they do correlate with 
molecular neuropathology, which seem to be distinctive among the various genes. (reviewed in 
(67). The first and main molecular neuropathological subtype is TDP-43 proteinopathy as 
defined above. This applies to all sporadic ALS and most non-SOD1 familial ALS. Ubiquitin and 
TDP-43 positive skeins define it and dense round inclusions deposited in the cytoplasm in the 
spinal motor neurons and the cortex, where they are primarily localized in motor areas (68). The 
inclusions are also seen glial cells.  
 
The second and newest defined neuropathological subtype of ALS is a variation on TDP-43 
proteinopathy related to expanded hexanucleotide repeats in c9orf72, which represents 33-40% 
of FALS and up to 7% of SALS. C9ORF72-associated cases have all the hallmark features of 13	 ﾠ
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TDP-43 proteinopathy, and, in addition, there are also abundant deposits of p62 and other 
markers in the cytoplasm and nucleus of neurons in the cerebellum, basal ganglia and 
hippocampus, features which are not robust in non-C9ORF72-associated cases (69, 70). p62 is 
a protein involved in both the proteosomal pathway and in autophagy, and this has relevance to 
the growing interest in these pathways in neurodegeneration.  
 
The third main molecular neuropathological signature of ALS applies to mutations in SOD1, 
which represents up to 20% of FALS and 1-2% of SALS. Most of the SOD1-associated 
neuropathology was reported prior to 2006 and TDP-43 and hexanucleotide repeat expanded 
C9ORF72 were identified and sorely needs to be updated (discussed by (71)). But in general, it 
is characterized by deposition in the cytoplasm of sometimes large amorphous conglomerates 
of ubiquitinated SOD1 protein that are negative for TDP-43 (68). There seems to be a greater 
burden on the LMN than UMN (72) and the degree of axon loss seem to be greater than 
neuronal loss, leading to the concept of it being a distal axonopathy (73). Misfolded SOD1 is 
present in SOD1-associated FALS but whether or not this is significant in SALS (74, 75) is 
disputed by emerging evidence that suggests if it is present at all, it is not prominent (76-78).  
 
The fourth main molecular neuropathological signature of ALS is FUS proteinopathy, which 
represents up to 3% of FALS and less than 1% of SALS. This neuropathological subtype is 
characterized by basophilic inclusions in the cytoplasm of neurons of the motor cortex and of 
spinal anterior horns, and by FUS-positive, TDP-43-negative immunoreactive inclusions in the 
cytoplasm of neurons and glia in the motor cortex, spinal anterior horns and various non-motor 
regions (79, 80). There appear to be different signatures in juvenile and adult forms of disease 
(80, 81). One recent report indicated FUS proteinopathy might be prominent in TDP-43-
proteinopathies if optimal technical protocols are used for detection (82), but so far this has not 
been verified by others.  14	 ﾠ
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WHAT DO CLINICAL HETEROGENEITY AND PATHOLOGICAL HOMOGENEITY INDICATE 
ABOUT UNDERLYING MECHANISMS? 
 
Hypotheses of propagation 
 
How phenotype, neuropathology and genetics relate to each other is not understood, but 
propagation of pathology has been identified as a principle component of pathobiology that 
could provide unified explanation. One hypothesis posits neuroanatomic propagation (83). ALS 
usually begins in discrete body regions and for these regions, the degree to which UMNs and 
LMNs are affected (the distribution of disease burden) is variably distributed (1). Once triggered, 
disease propagates to proximate neuroanatomical regions independently at the two levels and 
progressive motor neuron loss summates and then saturates neuropathologically (84). The rate 
of disease progression reflects both the kinetics of propagation and the distribution of the 
disease burden between UMN and LMN. In this light, PLS and PMA differ primarily in 
distribution of the pathologic burden between UMN and LMN levels, limb variants differ by 
neuroanatomic location of onset, and FTD and ALS differ in the cerebral distribution of 
pathology. A dramatic example is repeat-expanded C9ORF72-associated ALS/FTD, where a 
single disease mechanism leads to either ALS or FTD phenotype, each with their own 
heterogeneity.  
 
Different from neuroanatomic propagation is a hypothesis of propagation within neuronal 
networks. According to this hypothesis, the vast functional as well as structural networks in the 
CNS create a connectome (85). Neuronal networks may have selective vulnerabilities through 
natural anatomical patterns that underlie different neurodegenerative syndromes (86), possibly 15	 ﾠ
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through preferential spread (87). In support of this, advanced MRI data demonstrating ALS-
specific neurodegeneration within motor and extramotor networks is emerging (88-90). 
 
While propagation patterns have now been defined by many groups (91-95), other contributions 
to pathobiology are also emerging. One recent study identified that up to 14% of second regions 
involved in disease progression were not contiguous (95). Bifocal or multifocal onset has been 
proposed (96). Two recent studies using different approaches, one traditional groupings and 
one unbiased cluster analysis, identified a variety of demographic factors that are significant 
determinants of phenotype, (93, 97). Genetic syndromes, which are often focal in onset, also 
have other important biological determinants of phenotype based on factors other than 
propagation such as the tendencies for	 ﾠmutations in SOD1 and FUS tend to cause 
predominantly LMN syndromes, mutations in SOD1 and TARDBP to cause mostly ALS rather 
than FTD, and mutations in C9ORF72 to cause as much FTD as ALS. 
 
Parallels to FTD 
ALS and FTD overlap in many characteristics and they are increasingly viewed as part of a 
pathobiological spectrum. FTD has three main clinical phenotypes: primary progressive 
aphasia, semantic dementia and behavioral variant. As with ALS clinical phenotypes, here too 
the prime determinant is the focal neuroanatomic site of onset—left or right frontal or temporal 
regions. The neuropathology of FTD, referred to as frontotemporal lobar dementia (FTLD), has 
three main subtypes (Table 3): FTLD-U or TDP-43 (about 50%), FTLD-FUS (about 3-5%), and 
FTLD-tau (about 40-50%). FTLD-U or TDP-43 and FTLD-FUS overlap significantly with ALS, 
but FTLD-tau does not, except in one recent report (98). A main genetic overlap between ALS 
and FTD is with hexanucleotide repeat expanded C9ORF72 families, and lesser degrees of 
overlap are seen with the other ALS genetic mutations (reviewed in (67). Extensive studies over 
the last several years have sought correlations between FTD clinical phenotypes with FTLD 16	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neuropathological and genetic subtypes, and while trends have been identified, predictors and 
correlations are unclear and complex. The fact that FTD phenotypes can be as defined by the 
focal neuroanatomic site of onset as they can by any neuropathological or genetic feature 
suggests that FTD, like ALS,  may be viewed as a focally beginning and propagating disease 
and that, in turn, the pathobiology of propagation  is a principle a component of its biology. 
 
PATHOGENESIS 
 
Prime observations: It is reasonable to divide pathogenic mechanisms into three separate 
components: triggers, progression (or propagation), and neuronal death. The separable 
importance of disease trigger is highlighted by the observation that onset is highly variable in 
site and in distribution between UMN and LMN, in penetrance, and in age of onset. The 
separable importance of disease progression is highlighted by the highly variable patterns of 
progression and the progression rates, which suggest variable kinetics of propagation both in 
space and time. The separable importance of cell death is highlighted by the observation that 
select motor neuron degeneration is the ultimate result neuropathologically and that this 
summates over time and space. Many themes about molecular mechanisms of 
neurodegeneration have emerged over the past two decades and some of these are highlighted 
next. 
 
Motor neuron resistance and vulnerability in ALS: In ALS, the most vulnerable UMNs are layer V 
projection neurons in the primary motor cortex, and spinal motor neurons of the ventral horn. 
The most vulnerable regions and neurons in FTD are less clearly defined, but anterior cingulate 
and frontoinsular regions show early involvement, and these regions contain unique layer V 
projection neurons (von Economo neurons and fork cells). The coincidence of ALS and FTD in 
some patients raises the possibility that a shared cellular or molecular feature is present in 17	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cortical motor neurons and subspecialized layer V neurons of other cortical regions, which 
defines the sensitivity to degeneration in ALS/FTD. The prominent layer V degeneration in TDP-
43 transgenic models suggests the determinants of this shared vulnerability of layer V neurons 
may be present in rodents and be accessible to study. Improving our understanding of whether 
subspecialized layer V cells really are selectively vulnerable in ALS and FTD, and why, could 
provide a unique angle for understanding pathogenesis of these diseases. 
 
Among different LMN populations, the motor neurons subserving eye movements and pelvic 
sphincters are highly resistant compared with typical spinal motor neurons. Although often 
considered as a group, spinal motor neurons are highly diverse in terms of their morphology, 
connectivity, and functional properties and differ significantly in their response to disease. 
Recent studies of motor neuron diversity have clarified developmental mechanisms and 
provided novel insights into their neurodegeneration. Motor neurons of different classes and 
subtypes—fast/slow, alpha/gamma—are grouped together into motor pools, each of which 
innervates a single skeletal muscle. Distinct mechanisms regulate their development. In multiple 
contexts including ALS, spinal muscular atrophy and aging, fast-fatigable motor units 
degenerate early compared to motor neurons innervating slow muscles. Mechanisms for this 
could also relate to those conferring resistance to of those subserving eye movement and pelvic 
sphincter control. If we could understand why populations and subpopulations of motor neurons 
are resistant or vulnerable, we would have a strong rationale approach for intervention. One 
approach is through functional genomics using laser capturing and new genomic technologies. 
Extrinsic and intrinsic mechanisms that confer resistance represent promising therapeutic 
targets in these currently incurable diseases. 
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ALS as a systemic disease: As previously stated, there is a growing body of knowledge about 
the systemic changes that are occurring in ALS. These include ultrastructural abnormalities in 
hepatic cells, skin cells, muscle mitochondria, systemic glutamate metabolism, inflammatory 
cytokine production, immunological changes, glucose metabolism, and lipid metabolism. 
Skeletal muscle is the single largest organ by mass, constituting 40-45% of the entire body 
mass and is the end-organ of the motor neurons. Skeletal muscles generate target-derived 
neurotrophic factors that can substantially affect motor neuron survival. Part of the 
hypermetabolism that is becoming defined in ALS patients may be due to due to abnormal 
mitochondrial energy production in skeletal muscle(99), generating a large amount of radical 
oxygen species (100) that could interact with those from inside the CNS (101). Lipid peroxidase 
products are highly biologically active, causing cellular damage via apoptosis or nucleophilic 
action and these could be connected to ALS by way of APOE isoforms and/or paraoxonase I 
(PON1) or other pathways.  
 
The cellular neighborhood matters—Non-autonomous cell death: It is now clear that ALS 
associated with SOD1 mutations is non-cell autonomous, that is damage of the population of 
affected neurons depends upon complex interactions between them and their surrounding cells 
(102, 103). From analysis of mice that are mixtures of mutant-expressing SOD1 and normal 
cells, gene inactivation in selected cell types, and cell grafting to replace mutant expressing 
cells with normal ones, it appears mutant damage within motor neurons determines the timing of 
disease onset mutant damage within astrocytes and microglia drives disease progression. Thus, 
the cellular neighborhood matters. The exact roles of the different cell types are complex. 
Astocytes expressing ALS-related SOD1 mutations, can kill neighboring spinal motor neurons 
and are crucial to drive disease progression. This mechanism is unknown but the 
preponderance of evidence, from sporadic and familial ALS as well as rodent models, suggest a 
common loss of function of glutamate handling, through decreased expression and function of 19	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glutamate transporters(104-106), which is neurotoxic. Another could be mediated by a soluble 
toxic factor(s) that is protein in nature, thermo-labile, and negatively charged, but no in vivo 
evidence has emerged for this gain-of-toxicity mechanism. The identity of this toxic factor(s), the 
molecular pathways engaged, and protective small molecules have not yet identified exactly 
how this occurs. Microglia, the resident innate immune sentinels of the CNS, become activated, 
and evidence from both in vivo and in vitro models suggests that they can be either 
neuroprotective or cytotoxic, probably through the release of neurotrophic factors and cytokines 
(107-109). Activated microglia may switch from anti-inflammatory and neuroprotective to 
proinflammatory and neurotoxic, and a greater understanding of the numerous pathways 
involved could provide opportunities for novel therapeutic intervention. Oligodendroglia in the 
grey matter have recently been found to have a significant role in ALS. They are derived from 
NG2 cells, which are adult stem cells located throughout the neural axis. Oligodendrocytes 
provide trophic and possibly metabolic support to neurons and axons. They are massively 
proliferating in ALS, both mouse models and human disease, either because of some unknown 
signal or oligodendrocyte injury. Their exact role in ALS neurodegeneration and how this 
discovery may impact therapy remains to be determined. 
RNA processing and RNA toxicity: Views on pathogenesis are undergoing a sea-change from 
the recognition of the importance of the two RNA/DNA-binding proteins TDP-43 and FUS. Both 
are widely expressed, predominantly nuclear, have similar domains and prion-like properties, 
and have ALS mutations localized in the C-terminal region. They are both structurally close to 
the family of heterogeneous ribonucleoproteins (hnRNPs) and have been involved in multiple 
levels of RNA metabolism including transcription, RNA splicing, RNA transport, translation and 
microRNA processing (reviewed in (110-112). Importantly, splicing alterations (113, 114) and 
mRNA-editing errors (115-117) have been reported in sporadic ALS patients, albeit a role of 
TDP-43 or FUS in these modifications has not been defined. The emerging TDP-43 and FUS 
stories have led to the proposal that defects in RNA processing play a central role in 20	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neurodegeneration and this was further underscored by the recent recognition of intermediate 
length polyglutamine expansions in ataxin-2, another RNA binding protein, as a risk factor for 
ALS (118). At present, it is unresolved as to whether neurodegeneration is due to a loss of TDP-
43 or FUS function, a gain of toxicity or a combination of the two. The nuclear clearance of TDP-
43, and to less extent FUS, in neurons containing cytoplasmic aggregates, is consistent with 
pathogenesis driven, at least in part, by a loss of TDP-43 or FUS nuclear function. An 
alternative (not mutually exclusive) hypothesis, however, is that the accumulated proteins 
acquire a toxic function in the cytoplasm of affected neurons. This acquired toxic function may 
also rely on the RNA-binding properties of these proteins, as suggested by recent works in 
yeast, fruit fly and chick showing that the toxicity of TDP-43 aggregates is abolished when the 
RNA-binding property of the protein was removed (118, 119). 
 
In October, 2011, an expanded hexanucleotide repeat in C9ORF72 was identified in 
chromosome 9-linked ALS, FTD and their overlap, thus identifying the single most common 
genetic mechanism in ALS/FTD. This identification has three immediate implications. First, the 
same genetic defect can cause either ALS or FTD phenotype, thus re-enforcing that clinical 
phenotype does not directly reflect underlying molecular mechanism. Second, ALS and FTD 
now joins the group of expansion repeat disorders, a group of >22 inherited neurodegenerative 
diseases characterized by expanded nucleotide repeat sequences (microsatellites) in the 
genome. Third, two mechanisms seem most reasonable: gain-of-function due to production of 
toxic RNA; or loss of gene function, although no known functions of the C9ORF72 protein are 
currently known. A third possibility, that the protein acquires a toxic function, seems unlikely 
since the expanded repeat is intronic. 
 
Prion-like propagation: ALS and the linkage of ALS to FTLD could be explained on the basis of 
disease proteins such as SOD1 and TDP-43 propagating pathologically from cell to cell. This 21	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theme is emerging in a variety of different neurodegenerative diseases such as Alzheimer's 
disease, Parkinson's disease, as well as FTD and ALS, as it emerges that a number of proteins 
including alpha-synuclein, tau, abeta and mutant SOD1 may propagate within the central 
nervous system. Transmission or propagation is not the same as infectivity and the terms being 
used for these properties are “prion-like” or “prionoids” (Aguzzi, 2009), to distinguish them from 
bona fide prions, which are infectious. To date, there is no evidence that any other 
neurodegenerative disease besides prion diseases can be acquired by infection in humans 
(reviewed in (120)). Nevertheless, disease progression within the same individual, from a focal 
site of initiating damage throughout the central nervous system has been described for many 
neurodegenerative diseases, including ALS. While the molecular basis of these observations is 
not well understood, the propagation of pathological conformation of disease-related proteins 
(pathological templating) could underlie this phenomenon. Indeed, misfolded SOD1 and TDP-43 
were recently shown to induce a pathologic conformation on their natively folded counterparts 
when introduced on cells in culture (reviewed in (120)). This behavior is reminiscent of the 
pathologic prion protein and has now been demonstrated for several proteins that misfold and 
accumulate in neurodegeneration, including SOD1 and TDP-43 as well as A-beta, tau, and 
alpha synuclein (121-123). Preformed fibrils generated from recombinant alpha-synuclein, for 
example, when dripped onto primary cultures of wild-type neurons, will induce alpha-synuclein 
Lewy neurite pathology in processes, and this gets transported retrogradely back to the cell 
body where Lewy bodies are formed (124). Physical application to the cell bodies results in its 
transportation in the opposite direction, and there appears to be transmission throughout other 
parts of the brain. Not every neuron will be affected in the neuroanatomical pathways that 
connect one part of the brain to the other, but many are. And glial cells also can be induced to 
form alpha-synuclein pathology, at least in the transgenic mice. 
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“Molecular logic” of corticospinal motor neuron development, degeneration, and subcerebral 
projections: Interesting suggestions were made that common molecular origin during the 
development of corticospinal motor neurons (CSMN) and related subsets of cortical non-motor, 
cognitive association “subcerebral projection neurons” might explain at least some of the 
cognitive aspects of ALS (125). ALS might result, at least in part, from neuronal subtype-specific 
vulnerability due to errors introduced during neurodevelopment. Complex molecular controls 
regulate specification, differentiation, connectivity, and survival to create enormous complexity 
of CNS neuronal subtypes and their connections. Results over the past several years identify 
that the development and maintenance of corticospinal motor neurons and other neocortical 
projection neuron populations are controlled by a combinatorial set of complexly interacting 
developmental molecular regulators, largely transcription factors and co-regulators (126). These 
control key developmental processes including progenitor parcellation, subtype-specific 
differentiation, area identity, and axonal outgrowth (127). Loss-of-function and gain-of-function 
analyses for identified genes and molecules reveal a nested “molecular logic” of progenitor-
stage and post-mitotic molecular controls, many allele-specific and matching human disease 
distributions that exert either specific CSMN control or shared control over CSMN and related 
non-motor sub-cerebral projection neurons. The molecular-genetic controls occur in multiple 
steps and are parcellated in space, separated in distinct neuron subtypes in the same spatial 
position, and orchestrated over time via cross repression and acquisition of sequential stages of 
development, among other mechanisms. Most relevant to ALS and related UMN disorders and 
to disorders with non-motor, cognitive or sensory involvement, it now appears that a specific 
subtype of progenitors generates the entire set of CSMN, related subcerebrals, and 
corticothalamic projection neurons– all “corticofugal projection neurons”. Then, CSMN and all 
other subcerebrals share a distinct set of controls that are different from corticothalamics. Thus, 
CSMN and non-motor, cognitive and sensory subcerebrals are built on a “common chassis”, 
and common molecular abnormalities can predispose this broader population, or many narrower 23	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and more specific populations, to selective disease vulnerability, e.g. UMN disease with more or 
less non-motor involvement. Many developmental genes have now been identified as being 
associated with classical ALS. Thus, during initial development, errors might be introduced that 
lead to selective vulnerability and later degeneration.  
 
CONCLUDING REMARKS 
 
The holy grail of ALS is rationally designed therapy that effectively stops ALS neurogeneration 
in its advance. The fact that different gene mutations cause identical clinical phenotypes means 
that multiple mechanisms exist and ALS is a syndrome. But the fact that one single gene 
mutation causes many different ALS phenotypes means that there must be single common 
mechanisms and propagation of pathology is a principle component. With the transforming 
understanding of clinical, neuropathological, and molecular-genetic aspects of ALS over the last 
five years, this quest for rational fundamental therapy has become a realistic hope.  
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TABLE 1. ALS CLASSIFICATIONS 
Phenotype  Molecular Pathology  Genetics 
Typical ALS 
Bulbar/pseudobulbar ALS 
Limb onset variants: 
•  Typical limb onset  
•  Flail arm or bibrachial ALS 
•  Flail leg  
•  Polyneuritic variant 
•  Hemiplegic ALS (Mill’s variant) 
ALS with associated FTD or impairment 
of higher cortical function 
Primary lateral sclerosis 
Progressive muscular atrophy 
TDP-43 proteinopathy (ubiquitinated 
pathology) 
•  Without repeat expanded 
C9ORF72 
•  With repeat expanded C9ORF72 
SOD1 proteinopathy 
FUS proteinopathy (basophilic inclusion 
body disease (BIBD)) 
Sporadic ALS 
Familial ALS, incl.: 
•  ANG 
•  C9ORF72 
•  FIG4 
•  FUS 
•  OPTN 
•  SOD1 
•  TARDBP 
•  UBQLN 
•  VAPB 
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TABLE 2. PHENOTYPE CLASSIFICATION BASED ON CLINICALLY IMPUTED ANATOMY OF NEUROPATHOLOGY 
 
    CNS Anatomical Region Involved*  Innervated Peripheral Body Region Involved*
 
    UMN  LMN  Fronto-
temporal 
regions 
Bulbar 
muscles 
Limb muscles  Higher cortical 
function & 
behavior 
Based on 
Level of 
Involvement 
ALS  ++  ++  +/-  ++  ++  +/- 
PLS  ++++  +/-  +/-  ++  ++  +/- 
PMA  +/-  ++++  +/-  +/-  ++++  +/- 
Based on 
Body Region 
of 
Involvement 
Bulbar ALS  +/-  ++++  +/-  ++++  +/-  +/- 
Pseudobulbar 
ALS 
++++  +/-  +/-  ++++  +/-  +/- 
Limb ALS & 
variants 
+/-  ++++  +/-  +/-  ++++  +/- 
Associated 
cognitive 
FTD or 
behavioral/cog
+/-  +/-  ++++  +/-  +/-  ++++ 
	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ
*   +/- possible but not typical; ++ typical and to variable degree; ++++ primary feature 26	 ﾠ
	 ﾠ
changes   nitive 
impairment  27	 ﾠ
	 ﾠ
TABLE 3. ALS PROTEINOPATHIES: MAIN MOLECULAR NEUROPATHOLOGICAL FEATURES  
 
Proteinopathy  Phenotype  Gene  Main Molecular Features
† 
Motor cortex 
(UMN) 
Spinal anterior 
horn or brain 
stem motor 
nuclei (LMN) 
Fronto-temporal 
regions 
Miscellaneous 
(cerebellum, 
hippocampus) 
Descending 
axonal pathways 
(e.g. lateral 
columns) 
• FUS 
pathology 
• FUS 
proteinopathy 
	 ﾠ
•  Juvenile ALS 
•  Rare adult 
ALS (usu. with 
atypical sxs, e.g. 
oculo-motility, 
autonomic, 
cerebellar or 
cognitive 
dysfunction)  
•  FTD 
•  FUS-TLS  • Basophilic 
inclusions esp. 
juvenile cases;  
• FUS+,TDP43-, 
NCIs esp. 
juvenile cases;  
• FUS+,TDP43- 
GCIs esp. adult 
cases 
• Basophilic 
inclusions esp. 
juvenile cases;  
• FUS+,TDP43-, 
NCIs all cases; 
• FUS+,TDP43- 
GCIs esp. adult 
cases 
 
• Rare or none 
basophilic 
inclusions; 
• Rare or none 
FUS+, TDP43- 
NCIs; 
• FUS+, TDP43- 
GCIs in adult 
cases 
	 ﾠ
• Rare basophilic 
inclusions;  
• FUS+ TDP43-
NCIs & GCIs in 
other regions incl. 
substantia nigra, 
nuclei raphe, 
inferior olives, & 
dentate nucleus in 
adult cases 
• Degeneration & 
sclerosis 
	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ
† NCI = nuclear cytoplasmic inclusions; GCI = glial cytoplasmic inclusions 28	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• SOD1 
pathology
‡ 
•  ALS, usually 
LMN predom-
inant features 
Very rare FTD 
•  SOD1  Infrequent 
abnormalities as 
seen in spinal 
anterior horns 
• Weakly, 
ubiquitin+, 
TDP43-, SOD1-
, 
neurofilament+ 
intracytoplasmic 
hyaline 
conglomerates 
 
• Few reports, 
presumptively 
same as motor 
cortex 
 
• Changes also in 
Clarke’s nucleus, 
dorsal horn, 
nucleus 
ambiguous, & 
Onuf’s nucleus 
• Distal axonal 
degeneration 
• Also, 
degeneration in 
dorsal columns  
• TDP43 
pathology 
(non-
C9ORF72 
related); 
• TDP43 
protein-
•  ALS 
•  ALS-FTD  
•  FTD 
 
•  Most non-
SOD1-
associated 
FALS, including 
TARDBP 
•  All SALS 
• Ubiquitin+, 
TDP43+ NCIs & 
GCIs  
Ubiquitin+, 
TDP43+ NCIs & 
GCIs 
Ubiquitin+, 
TDP43+ NCIs & 
GCIs 
• No significant 
p62+ or UBQLN+ 
NCIs or GCIs in 
cerebellum and 
hippocampus 
• Degeneration & 
sclerosis 
	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ
‡ No primary FTD phenotypes have been defined by SOD1 pathology. 29	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opathies  
• Ubiquitinated 
pathology 
• TDP43 
pathology or 
TDP43 
protein-
opathies, 
C9ORF72 
variant 
 
•  ALS 
•  ALS-FTD 
FTD 
•  C9ORF72  • Ubiquitin+, 
TDP43+ NCI & 
GCI 
• Ubiquitin+, 
TDP43+ NCI & 
GCI 
• Ubiquitin+, 
TDP43+ NCI & 
GCI 
• p62+, UBQLN+, 
TDP43- NCIs & 
GCIs in 
cerebellum & 
hippocampus; 
TDP+ pathology is 
present but 
separable from 
p62 & UBQLN 
• Degeneration & 
sclerosis 
• Tau pathology 
(including 
FTLD-Tau with 
Pick bodies)
§; 
Tauopathies	 ﾠ
•  FTD 
•  Progressive 
supranuclear 
palsy 
•  Corticobasal 
•  MAPT  • Signature tau+, 
ubiquitin- 
TDP43- NCIs 
and GCIs 
• Few reports, 
presumptively 
negative (see §) 
• Signature tau+, 
ubiquitin-, TDP43- 
NCIs and GCIs 
• Pick bodies = 3R 
tau+ globular or 
spherical NCIs in 
the granule cells 
of dentate gyrus; 
• Presumptively 
negative 
	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	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§ Included here for comparison—no primary ALS phenotypes have been defined by tau+ neuropathology. 30	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syndrome 
•  Multiple 
system atrophy 
	 ﾠ
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